| Dr James B Powers, MD | |
|
96 Campus Drive, Suite 1, Scarborough, ME 04074 | |
| (207) 885-9905 | |
| (207) 396-5600 |
| Full Name | Dr James B Powers |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 33 Years |
| Location | 96 Campus Drive, Scarborough, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316974496 | NPI | - | NPPES |
| 243510099 | Medicaid | ME | |
| 30010405 | Medicaid | NH | |
| 030142 | Other | ANTHEM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | MD14508 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maine Medical Center | Portland, ME | Hospital |
| Memorial Hospital, The | North conway, NH | Hospital |
| Stephens Memorial Hospital | Norway, ME | Hospital |
| Southern Maine Health Care | Biddeford, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Maine Medical Partners | 9335043967 | 789 |
| Mainehealth | 7517860588 | 2067 |
| Memorial Hospital | 2365418993 | 86 |
News Archive
A team of scientists that included researchers from UCLA has discovered a novel mechanism of RNA regulation in embryonic stem cells. The findings are strong evidence that a specific chemical modification, or "tag," on RNA plays a key role in determining the ability of embryonic stem cells to adopt different cellular identities.
The bacterial cell wall that is the target of potent antibiotics such as penicillin is actually made up of a thin single layer of carbohydrate chains, linked together by peptides, which wrap around the bacterium like a belt around a person, according to research conducted by scientists at the California Institute of Technology (Caltech).
Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, LLC which would give Cancer Therapeutics a total of 51 percent and controlling interest of NanoTherapies.
We usually scold our children and teenagers for watching too much TV. It turns out that their grandmas and grandpas spend even more of their time watching TV, and it is not good for them either, according to researchers at the Stein Institute for Research on Aging and Rady School of Management at the University of California, San Diego School of Medicine.
OHSU Knight Cancer Institute Director Brian J. Druker, M.D., has been awarded the 2018 Tang Prize in Biopharmaceutical Science for his pioneering role in shaping the fields of precision medicine and targeted cancer drugs.
› Verified 7 days ago
| Entity Name | Mercy Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629078712 PECOS PAC ID: 6103737812 Enrollment ID: O20040217000943 |
News Archive
A team of scientists that included researchers from UCLA has discovered a novel mechanism of RNA regulation in embryonic stem cells. The findings are strong evidence that a specific chemical modification, or "tag," on RNA plays a key role in determining the ability of embryonic stem cells to adopt different cellular identities.
The bacterial cell wall that is the target of potent antibiotics such as penicillin is actually made up of a thin single layer of carbohydrate chains, linked together by peptides, which wrap around the bacterium like a belt around a person, according to research conducted by scientists at the California Institute of Technology (Caltech).
Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, LLC which would give Cancer Therapeutics a total of 51 percent and controlling interest of NanoTherapies.
We usually scold our children and teenagers for watching too much TV. It turns out that their grandmas and grandpas spend even more of their time watching TV, and it is not good for them either, according to researchers at the Stein Institute for Research on Aging and Rady School of Management at the University of California, San Diego School of Medicine.
OHSU Knight Cancer Institute Director Brian J. Druker, M.D., has been awarded the 2018 Tang Prize in Biopharmaceutical Science for his pioneering role in shaping the fields of precision medicine and targeted cancer drugs.
› Verified 7 days ago
| Entity Name | St Marys Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447226584 PECOS PAC ID: 0042107120 Enrollment ID: O20040303000236 |
News Archive
A team of scientists that included researchers from UCLA has discovered a novel mechanism of RNA regulation in embryonic stem cells. The findings are strong evidence that a specific chemical modification, or "tag," on RNA plays a key role in determining the ability of embryonic stem cells to adopt different cellular identities.
The bacterial cell wall that is the target of potent antibiotics such as penicillin is actually made up of a thin single layer of carbohydrate chains, linked together by peptides, which wrap around the bacterium like a belt around a person, according to research conducted by scientists at the California Institute of Technology (Caltech).
Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, LLC which would give Cancer Therapeutics a total of 51 percent and controlling interest of NanoTherapies.
We usually scold our children and teenagers for watching too much TV. It turns out that their grandmas and grandpas spend even more of their time watching TV, and it is not good for them either, according to researchers at the Stein Institute for Research on Aging and Rady School of Management at the University of California, San Diego School of Medicine.
OHSU Knight Cancer Institute Director Brian J. Druker, M.D., has been awarded the 2018 Tang Prize in Biopharmaceutical Science for his pioneering role in shaping the fields of precision medicine and targeted cancer drugs.
› Verified 7 days ago
| Entity Name | Maine Medical Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104921535 PECOS PAC ID: 9335043967 Enrollment ID: O20040331000274 |
News Archive
A team of scientists that included researchers from UCLA has discovered a novel mechanism of RNA regulation in embryonic stem cells. The findings are strong evidence that a specific chemical modification, or "tag," on RNA plays a key role in determining the ability of embryonic stem cells to adopt different cellular identities.
The bacterial cell wall that is the target of potent antibiotics such as penicillin is actually made up of a thin single layer of carbohydrate chains, linked together by peptides, which wrap around the bacterium like a belt around a person, according to research conducted by scientists at the California Institute of Technology (Caltech).
Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, LLC which would give Cancer Therapeutics a total of 51 percent and controlling interest of NanoTherapies.
We usually scold our children and teenagers for watching too much TV. It turns out that their grandmas and grandpas spend even more of their time watching TV, and it is not good for them either, according to researchers at the Stein Institute for Research on Aging and Rady School of Management at the University of California, San Diego School of Medicine.
OHSU Knight Cancer Institute Director Brian J. Druker, M.D., has been awarded the 2018 Tang Prize in Biopharmaceutical Science for his pioneering role in shaping the fields of precision medicine and targeted cancer drugs.
› Verified 7 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
A team of scientists that included researchers from UCLA has discovered a novel mechanism of RNA regulation in embryonic stem cells. The findings are strong evidence that a specific chemical modification, or "tag," on RNA plays a key role in determining the ability of embryonic stem cells to adopt different cellular identities.
The bacterial cell wall that is the target of potent antibiotics such as penicillin is actually made up of a thin single layer of carbohydrate chains, linked together by peptides, which wrap around the bacterium like a belt around a person, according to research conducted by scientists at the California Institute of Technology (Caltech).
Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, LLC which would give Cancer Therapeutics a total of 51 percent and controlling interest of NanoTherapies.
We usually scold our children and teenagers for watching too much TV. It turns out that their grandmas and grandpas spend even more of their time watching TV, and it is not good for them either, according to researchers at the Stein Institute for Research on Aging and Rady School of Management at the University of California, San Diego School of Medicine.
OHSU Knight Cancer Institute Director Brian J. Druker, M.D., has been awarded the 2018 Tang Prize in Biopharmaceutical Science for his pioneering role in shaping the fields of precision medicine and targeted cancer drugs.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James B Powers, MD 301c Us Route One, Scarborough, ME 04074 Ph: (207) 396-8600 | Dr James B Powers, MD 96 Campus Drive, Suite 1, Scarborough, ME 04074 Ph: (207) 885-9905 |
News Archive
A team of scientists that included researchers from UCLA has discovered a novel mechanism of RNA regulation in embryonic stem cells. The findings are strong evidence that a specific chemical modification, or "tag," on RNA plays a key role in determining the ability of embryonic stem cells to adopt different cellular identities.
The bacterial cell wall that is the target of potent antibiotics such as penicillin is actually made up of a thin single layer of carbohydrate chains, linked together by peptides, which wrap around the bacterium like a belt around a person, according to research conducted by scientists at the California Institute of Technology (Caltech).
Cancer Therapeutics, Inc. (OTCBB: CTHP), an emerging biotechnology business incubator with a specific emphasis on disruptive cancer treatments and nanotechnology, announced today it has signed a letter of intent to acquire another 26 percent interest in NanoTherapies, LLC which would give Cancer Therapeutics a total of 51 percent and controlling interest of NanoTherapies.
We usually scold our children and teenagers for watching too much TV. It turns out that their grandmas and grandpas spend even more of their time watching TV, and it is not good for them either, according to researchers at the Stein Institute for Research on Aging and Rady School of Management at the University of California, San Diego School of Medicine.
OHSU Knight Cancer Institute Director Brian J. Druker, M.D., has been awarded the 2018 Tang Prize in Biopharmaceutical Science for his pioneering role in shaping the fields of precision medicine and targeted cancer drugs.
› Verified 7 days ago
Dr. Mary C. Fahrenbach, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 96 Campus Drive, Suite 1, Scarborough, ME 04074 Phone: 207-885-9905 Fax: 207-396-5600 | |
Mark A Wrona, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 51 Us Route 1 Ste I, Scarborough, ME 04074 Phone: 207-303-3300 Fax: 207-250-2139 | |
Dr. Mylan C. Cohen, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 96 Campus Drive, Suite 1, Scarborough, ME 04074 Phone: 207-885-9905 Fax: 207-396-5600 | |
Mirle A Kellett, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 96 Campus Dr, Suite 1, Scarborough, ME 04074 Phone: 207-396-5611 | |
Dr. Warren D Alpern, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 96 Campus Dr, Suite 1, Scarborough, ME 04074 Phone: 207-396-5611 | |
Dr. Eleni Nicole Nackos, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 100 Campus Dr Unit 108, Scarborough, ME 04074 Phone: 207-303-3300 Fax: 207-250-2139 | |
Susan Miesfeldt, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 100 Campus Drive, Suite 110, Scarborough, ME 04074 Phone: 207-396-7678 Fax: 207-396-8766 |